<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164888</url>
  </required_header>
  <id_info>
    <org_study_id>CIVI 007-02-01</org_study_id>
    <nct_id>NCT04164888</nct_id>
  </id_info>
  <brief_title>Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy</brief_title>
  <official_title>A Placebo-controlled, Randomized, Phase 2a, Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CIVI 007 in Patients on a Background of Stable Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Civi Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Civi Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the clinical profile (lipid efficacy, safety and PK) across a number of doses
      of CIVI 007, a PCSK9 inhibitor. Patients to be evaluated will be on a stable background of
      statin therapy with or without ezetimibe.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of CIVI 007 adverse events</measure>
    <time_frame>2 month followup</time_frame>
    <description>Incidence of any drug-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of CIVI 007 safety laboratory abnormalities</measure>
    <time_frame>2 month followup</time_frame>
    <description>Incidence of clinically significant safety laboratory abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the pharmacodynamic effect of CIVI 007</measure>
    <time_frame>1 month followup</time_frame>
    <description>Percent change from baseline in PCSK9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the pharmacodynamic (PD) effect of CIVI 007</measure>
    <time_frame>2 month followup</time_frame>
    <description>Percent change from baseline in PCSK9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the lipid efficacy of CIVI 007</measure>
    <time_frame>1 month followup</time_frame>
    <description>Percent change from baseline in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the lipid efficacy of CIVI 007</measure>
    <time_frame>2 month followup</time_frame>
    <description>Percent change from baseline in LDL-C</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>CIVI 007, Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of a PCSK9 inhibitor- low dose given twice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIVI 007, Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of PCSK9 inhibitor- dose titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIVI 007, Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injection of PCSK9 inhibitor- high dose given twice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC injection matching PCSK9 inhibitor given twice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIVI 007</intervention_name>
    <description>hypercholesterolemia agent</description>
    <arm_group_label>CIVI 007, Dose A</arm_group_label>
    <arm_group_label>CIVI 007, Dose B</arm_group_label>
    <arm_group_label>CIVI 007, Dose C</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Body mass index (BMI) between 18.0 and 40.0

          2. Stable (&gt;4 weeks prior to the Screening Visit) dose of statin therapy with or without
             ezetimibe

          3. Fasting low-density lipoprotein cholesterol (LDL-C): ≥100 mg/dL for those without
             cardiovascular disease, or ≥70 mg/dL for those with cardiovascular disease.

          4. Fasting TGs &lt;400 mg/dL

        Key Exclusion Criteria:

          1. Women who are pregnant, nursing or breast feeding

          2. Currently prescribed a lipid lowering agent other than a statin or ezetimibe.

          3. Clinically significant disorder or laboratory abnormality that could contraindicate
             the administration of study drug, affect compliance, interfere with study evaluations,
             or confound the interpretation of study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L Shear, DrPH</last_name>
    <role>Study Director</role>
    <affiliation>CiVi Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munroe Falls</city>
        <state>Ohio</state>
        <zip>44224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

